MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Sanofi-Aventis SA (NYSE: SNY)
Finance & Acquisitions: Sanofi
Tidal Therapeutics
Parents
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Architects: Biotechnology_DNA, RNA, RNAi, siRNA & mRNA
Companies: Acquired_(M&A)
Finance & Acquisitions: Sanofi
Industry: Massachusetts
LabCentral
Children
2021: Sanofi CEO Paul Hudson dives deeper into mRNA, buying out an under-the-radar Fred Hutch spinout
2021: Sanofi Snatches Up Tidal Therapeutics in $470 Million Deal
Cambridge, Massachusetts
It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
Tidal Therapeutics received seed funding from Mission BioCapital, and was joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures, and AbbVie Ventures.
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge.
Jumps
AbbVie Inc. (NYSE:ABBV)
Fred Hutchinson Cancer Research Center
Multiple Myeloma Research Consortium (MMRC)